뒤로
Guangzhou Innogen Pharmaceutical Group Co., Ltd(02591.HK) 가격
02591.HK 주가 차트
INNOGEN-B (02591.HK)
Guangzhou Innogen Pharmaceutical Group Co., Ltd
HK$30.98
-3.18%
$-1.01
장 종료: Jan 16, 16:00:00 HKT
아직 데이터 없음Earnings FAQ
02591.HK의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd 02591.HK의 지난 분기 매출 실적은 어땠나요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd의 매출 추정치는 얼마인가요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd의 수익 품질 점수는 얼마인가요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd는 언제 수익을 보고하나요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd의 예상 수익은 얼마인가요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$31.02
시가
$32
일일 범위
$30.86 - $32.78
52주 범위
$28.4 - $74
거래량
410.8K
평균 거래량
667.1K
EPS(TTM)
-0.54
배당수익률
--
시가총액
$13.0B
INNOGEN-B란 무엇인가요?
Guangzhou Innogen Pharmaceutical Group Co., Ltd. engages in the production and distribution of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 105 full-time employees. The company went IPO on 2025-08-15. The firm is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The firm is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The firm principally conducts its businesses in the domestic market.